ARTICLE | Company News
Genentech, ImmunoGen, GlaxoSmithKline deal
July 1, 2002 7:00 AM UTC
GSK will not advance to Phase II trials IMGN's cantuzumab mertansine (huC242- DM1/SB-408075) to treat cancer under the terms of the companies' 1999 deal (see BioCentury Feb. 8, 1999). IMGN said it pla...